UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Juris ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - CBO Jeff Castelli - CDO Simon Harford - CFO Conference Call Participants Anupam Rama - JPMorgan Ellie Merle - UBS Kristen Kluska - Cantor Fitzgerald Tazeen Ahmad - Bank of America Operator Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' First Quarter 2024 Financial Results Conference Cal ...

Exhibit 99.1 Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates 1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold Guidance on Continued Strong Demand Strong Pombiliti+ Opfolda Launch with Increasing Rate of Commercial Patient Starts Reiterating Full-Year Non-GAAP Profitability Projected in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, NJ, Ma ...

1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold® Guidance on Continued Strong Demand Strong Pombiliti® + Opfolda® Launch with Increasing Rate of Commercial Patient Starts Reiterating Full-Year Non-GAAP Profitability Projected in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global bio ...

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year's report highlights the strength of the Company's corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensuring broad an ...

PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. Cowen 44th Annual Health Care Conference in Boston, MA, on Monday, March 4, 2024, at 11:10 a.m. E.T.Leerink Partners 2024 Global Biopharma Conference in Miami, FL on Monday, March 11, 2024, at 3:20 p.m. E.T. A live audio webcast of each presentation can also be accessed via the investors section of th ...

Amicus Therapeutics, Inc. (FOLD) reported fourth-quarter 2023 adjusted earnings of 1 cent per share against the Zacks Consensus Estimate of a loss of 6 cents. The company had reported a loss of 17 cents per share in the year-ago quarter.The year-over-year improvement can be attributed to higher revenues of Galafold (migalastat) and the successful ongoing commercial launch of the newly approved Pombiliti + Opfolda.Revenues in the fourth quarter totaled $115.1 million, up 31% year over year on a reported basi ...

Olivier Le Moal Shares of Amicus Therapeutics (NASDAQ:FOLD) are up modestly since my September 2023 update where I argued that the limited label of Pombiliti+Opfolda may not matter for the product combination's uptake because it would have been used like the label says anyway. And while there are no real pipeline updates to look forward to, the company may attract a different kind of investor base going forward - investors predominantly focused on revenue and earnings momentum. Amicus should start deliverin ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President & Chief Executive Officer Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Malcolm Kuno - JPMorgan Ritu Baral - TD Cowen Dae Gon Ha - Stifel Joseph Schwartz - Leerink Partners Ellie Merle - UBS Jeff Hung ...

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company ...